Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SHR-1918 added to stable lipid-lowering therapy in hyperlipidemia with inadequate lipid control
CTR20233436Phase 2Completed
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperlipidemia comparing SHR-1918 + stable lipid-lowering therapy with Placebo + stable lipid-lowering therapy (2 arms). Primary endpoint: Percent change from baseline in serum LDL-C at Week 16. Started Nov 2023; status: completed.
02
Drugs
SHR-1918
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on CTR20233436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233436.